Abstract Purpose of Review Triple-negative breast cancer (TNBC) accounts for 15–20% of
diagnosed breast tumours, with higher incidence in young and African-American women …

Chemotherapy is the primary established systemic treatment for patients with triple-negative
breast cancer (TNBC) in both the early and advanced-stages of the disease. The lack of …

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a
heterogeneous disease, not only on the molecular level, but also on the pathologic and …

Triple-negative breast cancer (TNBC) is a molecularly diverse disease. This heterogeneity
has limited the success of targeted therapy in unselected patients to date. Recent …

Opinion statement Triple-negative breast cancer (TNBC) accounts for 15% of all breast
cancers and is associated with poor long-term outcomes compared to other breast cancer …

Treatment of triple negative breast cancer (TNBC) is a clinically challenging problem due to
intriguing clinical and pathologic features of TNBC and natural or induced resistance to …

Triple-negative breast cancer (TNBC) is a heterogeneous disease; gene expression
analyses recently identified six distinct TNBC subtypes, each displaying a unique biology …

Triple negative breast cancer (TNBC) refers to a subgroup of breast carcinomas that do not
express the estrogen receptor, progesterone receptor, or human epidermal growth factor …

Introduction: Triple negative breast cancer (TNBC) is a heterogeneous disease associated
with a high risk of recurrence, and therapeutic options are currently limited to cytotoxic …

Triple-negative breast cancer (TNBC) represents 10–20% of all mammary tumors. It is often
found in younger women and has been associated with poor prognosis, due to aggressive …